

An Inhaled Allergen Challenge (IAC) study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma

Submission date 21/09/2009	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 11/11/2009	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 21/07/2016	Condition category Respiratory	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Brian Leaker

Contact details
Respiratory Clinical Trials Ltd (RCT)
Heart Lung Centre
Queen Anne Street Medical Centre
18-20 Queen Anne Street
London
United Kingdom
W1G 8HU

Additional identifiers

Protocol serial number
D4050169

Study information

Scientific Title

An exploratory, randomised, double-blind, placebo controlled, 14 day, two-way crossover, Inhaled Allergen Challenge (IAC) study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma

Acronym

IAC SMP-028

Study objectives

Primary:

To evaluate the effect on the late asthmatic response (LAR) to Inhaled Allergen Challenge in mild to moderate asthmatic subjects.

Secondary:

1. To evaluate the effect on the early asthmatic response (EAR), pharmacodynamics and lung function to Inhaled Allergen Challenge in mild to moderate asthmatic subjects
2. To evaluate the effect on bronchial hyper-reactivity as measured by adenosine monophosphate (AMP) challenge
3. To assess the safety and tolerability of treatment with repeat doses of SMP-028 in mild to moderate asthmatic subjects
4. To evaluate the multiple dose pharmacokinetics of SMP-028 and metabolites in subjects with mild to moderate asthma

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 21/05/10:

The Royal Free Hospital & Medical School Research Ethics Committee approved on the 1st of October 2009 (ref: D4050169 [IAC])

Primary study design

Interventional

Study design

Exploratory randomised double-blind placebo-controlled two-way crossover trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Asthma

Interventions

On Days 1 - 13, the dose of SMP-028 will be 80 mg twice a day or placebo. A single morning dose of 80 mg SMP-028 or placebo will be taken on Day 14.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

SMP-028

Primary outcome(s)

Mean baseline-corrected area under the forced expiratory volume in 1 second (FEV1) reduction curve from 4 to 10 hours after allergen challenge.

Key secondary outcome(s)

1. Early Asthmatic Response: FEV1
2. Exhaled NO
3. AMP PC20
4. Induced sputum cell counts
5. induced sputum inflammatory mediators
6. Adverse events
7. Laboratory safety tests
8. Vital signs
9. Physical examinations
10. 12-lead ECGs (electrocardiograms)
11. Pharmacokinetics of SMP-028 and its metabolites

Measured on Day 13/14 as appropriate. In addition, safety is followed up until 10 days +/- 3 days after the last dose on Day 14 of Period 2.

Completion date

01/04/2010

Eligibility

Key inclusion criteria

1. Male or female (of non childbearing potential) subjects aged between 18 and 65 years who have documented history of bronchial asthma
2. Demonstration of a positive wheal reaction to at least 1 of 3 allergens (house dust mite, grass pollen, cat hair and dander) on skin prick testing
3. Screening allergen challenge demonstrating that the subject experiences both an early and late asthmatic response.
4. Body mass index (BMI) within the range 19.0 - 32.0 kg/m² (inclusive)
5. Sensitivity to AMP with a provocative concentration of AMP

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

65 Years

Sex

All

Key exclusion criteria

1. Past or present disease which, as judged by the Investigator, may affect the outcome of this study
2. Subject has known history of uncontrolled hypertension or is hypertensive at the Screening visit
3. Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study drug
4. Symptomatic allergic rhinitis
5. History of life-threatening asthma

Date of first enrolment

01/11/2009

Date of final enrolment

01/04/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Respiratory Clinical Trials Ltd (RCT)

London

United Kingdom

W1G 8HU

Sponsor information

Organisation

Dainippon Sumitomo Pharma Europe Ltd (UK)

ROR

<https://ror.org/03sh4z743>

Funder(s)

Funder type

Industry

Funder Name

Dainippon Sumitomo Pharma Co. Ltd (Japan)

Alternative Name(s)

Dainippon Sumitomo Pharma Co., Ltd.

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Japan

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration